

Figure 1




Figure 2




Figure 3





Figure 4

FIGURE 5

14.1 vio.7 1-1 14.7 vio.7 1-1 14.7 vio.3 1-1 14.7 vio.3	
1-1 1(1) VA07 1-1 1(1) VA03	2.17 CAG GCT CAC TAY TAC TOT CAG GT TOG CAC ACC ACC ACC ACC ACC ACC ACC CAC ACC AC
3-1 16/9 VAO3	105 110 110 111 110 1110 1110 1110 1110
3.1	135 170 171 172 173 174 175 174 175 175 175 175 175 175 175 175 175 175
	105 110 110 110 110 110 110 110 110 110
3-10 PP 05	155 210 215
3-10 PP 05	ITA GOS AND GOC ACC ING AND AND GOC CAN GING GING GAN GAN GAN GAN THE THE THE THE WAY AND
FF 44	CDR3 116 118 110 CAG GTC AGT AAT CGG CC TCA GGG GTT TCT AAT CGG
2-14 PP 14	210 210 215 210 210 215 210 210 210 210 210 210 210 210 210 210
3-19 PP 03	60 15 110 110 110 110 110 110 110 110 110
3-19 PP 03	200 6CT CAG GCA CAT CAG UCT CAC TAT TAC TUT AAC TCC CGG CAC
3-23 SORT 04	150 COM 165 165 165 160 160 160 160 160 160 160 160 160 160
3-23 SORT 04	TEA TAT ECA GOAT ACT ACT ATTC T TWG GTO TTK, COC GOA GOG ACC AAG CTG ACC ACC ACC ACC ACC ACC ACC ACC ACC AC

Somatic hypermutation in translocus V genes

No of Mutations





Heavy chain

Kappa chain

Lambda chain

Human antibody responses in





Serum dilution

7783.26 from a 5-feature translocus mouse A human IgM,λ monoclonal anti-human PLAP

